A Saskatoon-based company that focuses on the development and commercialization of therapeutic products that contain cannabis compounds has received its Health Canada Medical Sales License.
A news release from ZYUS Life Sciences says the company has made significant strides to improving patient quality of life including the launch of pre-clinical trials to determine the impact of cannabis derivatives on mental and neurological health conditions and successfully achieving a plant-made potential antigen for the COVID-19 vaccine.
CEO Brent Zettl says, “The receipt of our Medical Sales License is another important step towards restoring health and well-being to patients here in Canada and around the world.”
Now that ZYUS has the sales license, the company can now apply to Health Canada to amend its processing license to add cannabis extracts and topical formulations, and will launch sales to registered patients before the end of this year.
Prospective patients and healthcare practitioners can contact ZYUS for more information.